DrugPatentWatch Database Preview

Details for Patent: RE38551

Which drugs does patent RE38551 protect, and when does it expire?

Patent RE38551 protects VIMPAT and is included in three NDAs.

This patent has nineteen patent family members in eleven countries.

Summary for Patent: RE38551

Title:	Anticonvulsant enantiomeric amino acid derivatives
Abstract:	The present invention is directed to a compound in the R configuration about the asymmetric carbon in the following formula: ##STR1## pharmaceutical compositions containing same and the use thereof in treating CNS disorders in animals.
Inventor(s):	Kohn; Harold (Chapel Hill, NC)
Assignee:	Research Corporation Technologies, Inc. (Tucson, AZ)
Application Number:	10/058,634
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE38551
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent RE38551

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Ucb Inc	VIMPAT	lacosamide	SOLUTION;INTRAVENOUS	022254-001	Oct 28, 2008		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE	➤ Sign Up
Ucb Inc	VIMPAT	lacosamide	SOLUTION;INTRAVENOUS	022254-001	Oct 28, 2008		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE	➤ Sign Up
Ucb Inc	VIMPAT	lacosamide	SOLUTION;ORAL	022255-001	Apr 20, 2010		RX	Yes	Yes	➤ Sign Up	➤ Sign Up		Y		METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER	➤ Sign Up
Ucb Inc	VIMPAT	lacosamide	SOLUTION;ORAL	022255-001	Apr 20, 2010		RX	Yes	Yes	➤ Sign Up	➤ Sign Up		Y		METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent RE38551

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
5,773,475	Anticonvulsant enantiomeric amino acid derivatives	➤ Sign Up
6,048,899	Anticonvulsant enantiomeric amino acid derivatives	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent RE38551

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Portugal	1038522	➤ Sign Up
Portugal	888289	➤ Sign Up
Netherlands	300376	➤ Sign Up
Japan	3145414	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: RE38551

For more information try a trial or see the plans and pricing